Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (October 2017)
18 slides from Resonance Health's investor presentation, Oct 19, 2017
Slide 1: Resonance Health Ltd Investor Handbook
For personal use only Resonance Health Ltd Investor Handbook Be Better Informed
Slide 2: Contents
2 CONTENTS For personal use only About Resonance................................................................................ 3 Our Solutions: Product Portfolio...................................................... 1 1 Our Vision & Mission.. .......................................................
Slide 3: About Resonance
3 ABOUT RESONANCE For personal use only “Resonance Health provides medical diagnostic solutions for the measurement of Another more recent product measures iron levels in the bone marrow and has iron-levels, fat-content and other biomarkers in human organs including the liver, application for the ap
Slide 4: Our Vision & Mission
4 OUR VISION & MISSION For personal use only • To better inform medical practitioners and patients • To be a leader in radiological medical diagnostic solutions • To consistently deliver high-quality, customer-focussed services • To continually develop and commercialise new products and solutions •
Slide 5: Why Invest in Resonance
5 WHY INVEST IN RESONANCE For personal use only 1. Artificial Intelligence (AI) / R&D Investment: 3. Reputation for Excellence Combined with Commercial Focus: • Resonance is at the forefront of AI in medical radiological diagnostics • 230 radiology clinics world-wide now offer FerriScan services • D
Slide 6: Global Footprint Map
6 GLOBAL FOOTPRINT MAP For personal use only Western North Europe America Asia Africa South Existing Markets America Australia & Targeted Markets New Zealand *Resonance already provides clinical trial services in some emerging markets
Slide 7: Company History & Projected Milestones
7 COMPANY HISTORY & PROJECTED MILESTONES For personal use only 2000 2005 2011 2016 2017 2017 2017 Discovery is initially FerriScan obtains Cardiac T2* achieves Regulatory clearance Leading NGO identifies Regulatory clearance Strategic Partnership ‘spun-off’ from UWA into regulatory clearance regulat
Slide 8: Corporate, Operational & Financial Highlights
8 CORPORATE, OPERATIONAL & FINANCIAL HIGHLIGHTS For personal use only FerriScan + Cardiac T2* Service Model 2017 Financial Highlights: • Revenue of $2.6m and net Loss of $384k* • R&D and marketing investment of $1.1m • Eligible for R&D tax incentives and rebates • High repetition of business (i.e. r
Slide 9: Board & Management
9 BOARD & MANAGEMENT For personal use only BOA R D Dr Martin Blake Non-Exec Chair Radiologist & Nuclear Physician “The Resonance Health team has a strong passion for Mr Simon Panton Non-Exec Director Business Executive & Largest RHT Shareholder healthcare and is dedicated to Dr Travis Baroni Non-Exe
Slide 10: Human Iron Levels & Organ Fat – The Importance of Accurate Measurement
10 HUMAN IRON LEVELS & ORGAN FAT – THE IMPORTANCE OF ACCURATE MEASUREMENT For personal use only “The need for a reliable way of measuring Iron load in the heart and liver cannot be “Fat in and around human organs is related to disease and numerous health underscored enough, first and above all for t
Slide 11: Product Portfolio
11 PRODUCT PORTFOLIO For personal use only Products in Development: “What if an algorithm could tell you whether you have cancer based on your CT scan or mammography 1. Artificial Intelligence / Machine Learning LIC Assessment exam? While I am certain that radiologists’ creative 2. Liver Fibrosis /
Slide 12: FerriScan & Cardiac T2* (Iron Tests)
12 FERRISCAN & CARDIAC T2* (IRON TESTS) For personal use only What it is: • Measures, diagnoses and manages iron in the liver and heart “FerriScan is globally recognised in the clinical • Alternative to FerriScan is liver biopsy which is invasive and expensive community as the gold standard method f
Slide 13: HepaFat-Scan & Pancreas Fat (Fat Tests)
13 HEPAFAT-SCAN & PANCREAS FAT (FAT TESTS) For personal use only What it is: • Hepafat-Scan assesses amount of fat in the liver, obtained regulatory clearance in 2014 “HepaFat-Scan has substantial advantages • Application in diagnosis/management of fatty liver disease, diabetes, metabolic disease, a
Slide 14: Bone Marrow R2-MRI Iron Assessment (Iron Test)
14 BONE MARROW R2-MRI IRON ASSESSMENT (IRON TEST) For personal use only What it is: • MRI based test for assessing iron levels in the bone marrow “A non-invasive standardised method for assessing • Decreased and increased bone marrow iron have clinical significance bone marrow iron may provide impor
Slide 15: Artificial Intelligence
15 ARTIFICIAL INTELLIGENCE For personal use only What it is: Commercialisation: “We urge all centres and health care professionals to ensure that they are using only validated techniques. • Resonance has developed an Artificial Intelligence • Globally there over 330K people born annually TIF is seek
Slide 16: Products in Development
16 PRODUCTS IN DEVELOPMENT For personal use only LIVER FIBROSIS/INFLAMMATION MEASUREMENT/BLOOD MARKER TEST “Considered the ‘gold standard’ for determining the extent of liver disease, several points of interest What it is: regarding liver biopsy should be considered. Liver biopsy is not always accur
Slide 17: Disclaimer
17 19 DISCLAIMER DISCLAIMER For personal use only Forward Looking Statements: officers, or indirect employees, related consequential (and bodies corporate whether arisingand agents out of disclaim any use all liability, or reliance on thisdirect, indirect or consequential presentation (andThis or in
Slide 18: Annexes - Press
18 ANNEXES - PRESS Friday 25 August 2017 | The Australian Financial Review | www.afr.com 33 ADVERTISING FEATURE AI in medical imaging Virtual mind reads liver signs Inthewaragainstliverdisease,radiologistsare For personal use only gettinghelpfromanunexpectedsource–artificial intelligence. Perthhealth
Resonance Health — Investor Presentation (October 2017) on 6ix